Marksans Pharma Cetirizine Hydrochloride Tablets get USFDA okay
Mumbai: Marksans Pharma Limited today announced that the company has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine
Hydrochloride Tablets 5 mg and 10mg.
It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose.
The product will be marketed under store brand labels and is comparable to the brand Zyrtec.
Read also: UK MHRA okays Marksans Pharma anti-diarrhoea drug Loperamide
Marksans Pharma, headquartered at Mumbai (India) is a global pharmaceutical company.
The company's key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others.
Read also: Marksans Pharma gets USFDA nod for Acetaminophen ER Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.